Dietrich A. Stephan
Founder of 6 different companies, including: NeuBase Therapeutics, Inc., Lifecode, Inc. and LifeX Holdings LLC, Dietrich A. Stephan is an entrepreneur and businessperson who has been at the head of 6 different companies and is Chairman for Peptilogics, Inc., Chairman, President, CEO & Chief Financial Officer at NeuBase Therapeutics, Inc. (which he founded in 2018), Director & Chief Scientific Officer at Life Technologies Clinical Services Lab, Inc. (which he founded in 2006) and Chairman-Neuroscience Microarray Consortium at National Institutes of Health. He is also on the board of Sharp Edge Labs, Inc., FarmaceuticalRX LLC, FRX Growth Partners LLC and Epistemix and Member of National Institute of Health Policy and Partner at Cyto Ventures.
In the past he was Chairman at DiaVacs, Inc. (he founded the company), Chief Executive Officer of LifeX Holdings LLC (he founded the company), President & Chief Executive Officer at Neubase Therapeutics, Inc., Chief Scientist at Lifecode, Inc. (he founded the company in 2011), Director-Neurogenomics Division at Amnestix, Inc. (he founded the company in 2006), Professor at the University of Pittsburgh, Faculty Member at George Washington University, Faculty Member at Arizona State University, Faculty Member at The Johns Hopkins University, Faculty Member at the University of Arizona, Executive Director-Gene Partnership at The Children's Hospital Corp., Chairman-Neurogenomics Department & Professor at Translational Genomics Research Institute and Executive Director-Gene Partnership at Harvard Medical School.
Dr. Stephan received an undergraduate degree from Carnegie Mellon University and a doctorate from the University of Pittsburgh Graduate School of Public Health.
|04/26/2021||12,000||Acquisition at $5 per share.||60,000|
|12/01/2020||1,273,820||Gift at $0 per share.||0|
|12/01/2020||1,273,819||Gift at $0 per share.||0|
|11/30/2020||1,273,819||Gift at $0 per share.||0|
|11/23/2020||2,547,639||Gift at $0 per share.||0|
|06/09/2020||1,275||Acquisition at $7.73 per share.||9,855|
|05/21/2020||1,250||Acquisition at $8.09 per share.||10,112|
|04/30/2020||10,000||Acquisition at $6 per share.||60,000|
|07/12/2019||2,547,639||Award at $0 per share.||0|